OptiMedis Management Board reconstituted

The year 2020 will bring change to the Board of OptiMedis AG: after more than ten years at OptiMedis, Deputy Chairman of the Board Dr Alexander Pimperl takes on new professional challenges as Director Data Insights & Business Intelligence at AstraZeneca Germany. “It is incredibly difficult for me to say goodbye to OptiMedis after more than ten years of intensive cooperation. On the other hand, I look forward to accompanying one of the world's leading companies in the research-based pharmaceutical industry on the path of digital transformation, setting up the newly founded Data Insights & Business Intelligence team, and contributing my experience in data analytics and the conception and management of value-orientated supply systems,“ he explains. “I remain very close to OptiMedis and my colleagues, and will follow and accompany the development and further implementation of our OptiMedis care model. I have helped to develop the model and, because of my international experience, also consider it a successful model of integrated population-orientated care. I am particularly pleased that it is now to be implemented in a fourth region in Germany (more informations in January).“

The CEO of OptiMedis, Dr Helmut Hildebrandt, emphasises: "I do not only appreciate Alexander Pimperl for his extraordinary professional competence – he has also become very dear to me and my team in the many years of cooperation. This gap will be difficult to fill. At the same time, I am pleased that our team is growing overall and that we will be welcoming four new employees in various departments over the coming months.”

The department headed by Dr Alexander Pimperl will now be absorbed in the expanded department “Analytics, Research and Innovation“ of the deputy CEO of OptiMedics, Dr Oliver Groene (This email address is being protected from spambots. You need JavaScript enabled to view it.). Pascal Wendel (This email address is being protected from spambots. You need JavaScript enabled to view it.) will take over the management of the Health Data Analytics department. As before, the contact person for medical aids and investors is Dr Helmut Hildebrandt (This email address is being protected from spambots. You need JavaScript enabled to view it.).